Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clinical Trial
Stock Information for Medicenna Therapeutics Corp.
Loading
Please wait while we load your information from QuoteMedia.